In this study, LF-C3G-encapsulated nanoparticles (LF-C3GNPs) were engineered and thoroughly characterized to assess their therapeutic potential against LTA-induced inflammation and oxidative stress in mastitis, primarily via modulation of the Sesn2/Nrf2 signaling pathway (Scheme 1). The gene discussed is SESN2; the disease is mastitis.